Antibody engineering and its therapeutic applications
- 6 August 2021
- journal article
- other
- Published by Taylor & Francis in International Reviews of Immunology
- Vol. 42 (2) , 156-183
Abstract
As a natural function, antibodies defend the host from infected cells and pathogens by recognizing their pathogenic determinants. Antibodies (Abs) gained wide acceptance with an enormous impact on human health and have predominantly captured the arena of bio-therapeutics and bio-diagnostics. The scope of Ab-based biologics is vast, and it is likely to solve many unmet clinical needs in future. The majority of attention is now devoted to developing innovative technologies for manufacturing and engineering Abs, better suited to satisfy human needs. The advent of Ab engineering technologies (AET) led to phenomenal developments leading to the generation of Abs-/Ab-derived molecules with desirable functional properties proportional to their expanding requirements. Evolution brought by AET, from the naturally occurring Ab forms to several advanced Ab formats and derivatives, was much needed as it is of great interest to the pharmaceutical industry. Thus, numerous advancements in AET have propelled success in therapeutic Ab development, along with the potential for ever-increasing improvements. Unique characteristics of Abs, such as its diversity, specificity, structural integrity and an array of possible applications, together inspire continuous innovation in the field. Overall, the AET could assist in conquer of several limitations of Abs in terms of their applicability in the field of therapeutics, diagnostics and research; AET has so far led to the production of next-generation Abs, which have revolutionized these arenas. Here in this review, we discuss the various distinguished engineering platforms for Ab development and the progress in modern therapeutics by the so-called “next-generation Abs.” Graphical AbstractKeywords
This publication has 165 references indexed in Scilit:
- Brentuximab vedotinNature Reviews Drug Discovery, 2012
- Research and development of next generation of antibody-based therapeuticsActa Pharmacologica Sinica, 2010
- Structure and function of immunoglobulinsJournal of Allergy and Clinical Immunology, 2010
- Functional Characterization of N297A, A Murine Surrogate for low-Fc Binding Anti-Human CD3 AntibodiesImmunological Investigations, 2009
- Properties, production, and applications of camelid single-domain antibody fragmentsApplied Microbiology and Biotechnology, 2007
- Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides 1 1Edited by I. A. WilsonJournal of Molecular Biology, 2000
- Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues 1 1Edited by J. A. WellsJournal of Molecular Biology, 1999
- Expanding the conformational diversity by random insertions to CDRH2 results in improved anti-estradiol antibodies 1 1Edited by A. R. FershtJournal of Molecular Biology, 1999
- By-passing immunisationJournal of Molecular Biology, 1992
- Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coliNature, 1989